Clinical Trials, Study Results and Plain Language Results Summaries - Clinical Trials - Research & Development

All clinical trial information provided by Daiichi Sankyo on this site and on other clinical trial registries sites, such as the US ClinicalTrials.gov, EU CTIS/EU CTR, Japan jRCT, etc. are meant to ensure transparency regarding the clinical trials and is not intended to promote or commercialize Daiichi Sankyo’s medicines.
Please note that the results of each clinical trial shown are based on findings available at the completion of the trial and may not represent the most comprehensive or up-to-date information.
For detailed information about approved uses of medications, please refer to the official package inserts. The information on our site and linked sources are not a substitute for a doctor's advice. If you have any questions, please consult your doctor.

Search by Disease Name, Project Code, Generic Name or Study Code

Find clinical trial information available in Japanese language

A

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Azelnidipine	CALBLOCK®	Hypertension	CB502-021	jRCT1080220028
AC430	Discontinued	Healthy Participants	AC430-001	NCT01287858
AC480IV	Discontinued	Advanced Solid Cancer	AC480IV-001	NCT01245543
ASB17061	Discontinued	Atopic Dermatitis	ASBI 704	NCT01756898	Tabulated Results (CT.gov)

B

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Baclofen	GABALON®	Spastic Paralysis	DL404-02P	jRCT1080220031	Summary Results (jRCT)
Baclofen	GABALON®	Spastic Paralysis	DL404-01	jRCT2080220061
Bempedoic Acid	Nilemdo®	Healthy Participants	DSE-BMP-0004-CIS-MA	NCT07201545
Bempedoic Acid	Nilemdo®	Healthy Participants	DSE-BMP-0002-CIS-MA	NCT07182383

C

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-238	jRCT2031230423
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-237	jRCT2031230424
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-214	jRCT2031220665	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-212	jRCT2071220111	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-203	jRCT2031220399	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-202	jRCT2031220400	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-103	jRCT2031220264	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-146	jRCT2071210106	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-116	jRCT2071210086	Summary Results (jRCT)
COVID-19 mRNA Vaccine	DAICHIRONA®	Prevention of Infectious Disease by SARS-CoV-2	DS5670-A-J101	NCT04821674 jRCT2071200110	Summary Results (jRCT)
Carperitide	HANP®	Congestive Heart Failure; Myocardiopathies	03-0-162	NCT00259038
Carvedilol	ARTIST®	Atrial Fibrillation	DQ2466-A-J301	jRCT2080222155
Colesevelam	WELCHOL®	Pediatric Type 2 Diabetes Mellitus	WEL-A-U307	NCT01258075	Tabulated Results (CT.gov)
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-A-U306	NCT00789750	Tabulated Results (CT.gov)
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-305	NCT00789737	Tabulated Results (CT.gov)
Colesevelam	WELCHOL®	Hyper-cholesterolemia	WEL-407	NCT00755352
Colesevelam	WELCHOL®	Hyper-cholesterolemia	WEL-406	NCT00754507
Colesevelam	WELCHOL®	Hyper-cholesterolemia; Hyperlipidemia, Familial Combined	WEL-403	NCT00754039
Colesevelam	WELCHOL®	Hyper-cholesterolemia	WEL-405	NCT00753779
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus; Hyper-cholesterolemia; Pre-diabetes	WEL-411	NCT00570739	Tabulated Results (CT.gov)
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-409	NCT00484419	Tabulated Results (CT.gov)
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-202	NCT00361153
Colesevelam	WELCHOL®	Hyper-cholesterolemia	WEL-408	NCT00185107
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-304	NCT00151762
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-302	NCT00151749
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-303	NCT00147758
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-201	NCT00147745	Tabulated Results (CT.gov)
Colesevelam	WELCHOL®	Type 2 Diabetes Mellitus	WEL-301	NCT00147719
Colesevelam	WELCHOL®	Hyper-cholesterolemia	WEL-410	NCT00145574 2005-003511-75	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Cevimeline	EVOXAC®	Xerostomia	CDR0000068698	NCT00017511
CS-0777	Discontinued	Multiple Sclerosis	CS0777-A-U102	NCT00616733
CS-1036	Discontinued	Diabetes	CS1036-A-A201	jRCT2080221036
CS-1036	Discontinued	Diabetes	CS1036-A-J202	jRCT2080221087
CS-4771	Discontinued	Healthy Participants	CS4771-A-J105	jRCT2080221894
CS-801	Discontinued	Overactive Bladder	150-010	jRCT2080220025
CS-801	Discontinued	Overactive Bladder	150-006	jRCT2080220026
CS-8080	Discontinued	Healthy Participants	CS8080-A-U102	NCT00796575
CS-8080	Discontinued	Healthy Participants	CS8080-A-U101	NCT00613431
CS-917	Discontinued	Type 2 Diabetes Mellitus	CS0917-A-U205	NCT00290940
CS-917	Discontinued	Type 2 Diabetes Mellitus	CS0917-A-E-107	2004-003195-11	Summary Results (EU-CTR)

D

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Datopotamab Deruxtecan	DATROWAY®	Urothelial Cancer; Bladder Cancer	TROPION-Urothelial03 DS1062-328	NCT07129993 jRCT2061250062
Datopotamab Deruxtecan	DATROWAY®	Advanced Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer	DS1062-0003-EAP-MA	NCT06279728
Datopotamab Deruxtecan	DATROWAY®	Non-small Cell Lung Cancer	TROPION-Lung08 DS1062-A-U304	NCT05215340 2023-507933-12-00 jRCT2061210074 CTR20220788 (CN) 1119004542 (TW) MFDS Korea
Datopotamab Deruxtecan	DATROWAY®	Non-small Cell Lung Cancer	TROPION-Lung07 DS1062-A-U303	NCT05555732 2022-500802-16-00 jRCT2061220066 CTR20230083 (CN) 1119057271 (TW) MFDS Korea
Datopotamab Deruxtecan	DATROWAY®	Non-small Cell Lung Cancer	TROPION-Lung01 DS1062-A-U301	NCT04656652 2020-004643-80 jRCT2071200104 CTR20220593 (CN) 1091497504 (TW) MFDS Korea	Tabulated Results (CT.gov) (EU-CTR)
Datopotamab Deruxtecan	DATROWAY®	Non-small Cell Lung Cancer	TROPION-Lung05 DS1062-A-U202	NCT04484142 2024-511449-21-00 jRCT2041200097 1096027316 (TW) MFDS Korea	Tabulated Results (CT.gov) (EU-CTR)
Datopotamab Deruxtecan	DATROWAY®	Non-small Cell Lung Cancer	TROPION-Lung02 DS1062-A-U102	NCT04526691 2023-508003-20-00 jRCT2031200193 1101492552 (TW)
Datopotamab Deruxtecan	DATROWAY®	Solid Cancer; Non-Small-Cell Lung Cancer; Triple Negative Breast Cancer	TROPION-PanTumor01 DS1062-A-J101	NCT03401385 jRCT2080223756
DS3610		Solid Tumors; Metastatic Solid Tumors	DS3610-071	NCT07159126 jRCT2031250388
DS3790		Hematological Malignancies	DS3790-076	NCT07220616 jRCT2031250487
DS5361		Advanced Solid Tumor	DS5361-061	NCT07182591 jRCT2031250489
DS9051		Advanced or Metastatic Adrenocortical Carcinoma; Metastatic Castration-resistant Prostate Cancer	DS9051-079	NCT07189403
DS-1001		Glioma	DS1001-A-J201	NCT04458272 jRCT2080225243
DS-1001		Glioma	DS1001-A-J101	NCT03030066 jRCT2080223424
DS-1001		Healthy Participants	DS1001-171	jRCT2071240033	Summary Results (jRCT)
DS-1103		Advanced Solid Tumor; Breast Cancer	DS1103-074	NCT05765851 2023-503965-48-00
DS-2243		Sarcoma; Solid Tumors	DS2243-054	NCT06644755 MFDS Korea
DS-3939		Advanced Solid Tumor; Metastatic Solid Tumor	DS3939-077	NCT05875168 jRCT2031230233 CTR20252034 (CN) MFDS Korea
DS-7011		Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus	DS7011-107	NCT05638802 jRCT2031230588 CTR20240595 (CN)
DS-7011		Healthy Participants	DS7011-A-U101	NCT05203692
DS-7830		Healthy Participants	DS7830-131	jRCT2051230152	Summary Results (jRCT)
DS-9606		Ovarian Cancer; Germ Cell Tumor; Advanced Solid Tumors	DS9606-137	NCT05394675 2022-000120-38
Denosumab	PRALIA®	Rheumatoid Arthritis	AMG162-D-J301	NCT01973569 jRCT2080222228	Tabulated Results (CT.gov) Summary Results (jRCT)
Denosumab	RANMARK®	Giant Cell Tumor of Bone	AMG162-B-J201	jRCT2080221624
Denosumab	PRALIA®	Rheumatoid Arthritis	AMG162-D-J201	jRCT2080221226	Summary Results (jRCT)
Denosumab	PRALIA®	Osteoporosis	AMG162-A-J301	NCT00680953 jRCT2080220769	Tabulated Results (CT.gov)
Diphtheria Pertussis Tetanus Combined Vaccine	Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine	Prevention of Diphtheria; Tetanus; Pertussis	VN0103-A-J301	jRCT2080222484
DS-1205	Out-licensed	Non-small Cell Lung Cancer	DS1205-A-J102	NCT03599518 jRCT2080223968	Tabulated Results (CT.gov) Summary Results (jRCT)
DS-1205	Out-licensed	Non-small Cell Lung Cancer	DS1205-A-U101	NCT03255083 2017-000542-21 1076027711 (TW)	Tabulated Results (CT.gov)
DS-6051	Out-licensed	Advanced Solid Malignant Tumors	DS6051-A-J102	NCT02675491 jRCT2080223057
DJ-927	Discontinued	Colorectal Cancer	CDR0000356034	NCT00080834
DJ-927	Discontinued	Solid Cancer	CDR0000346368	NCT00077077
DJ-927	Discontinued	Non-small Cell Lung Cancer	927E-PRT007	2004-000696-34	Summary Results (EU-CTR)
DS-1040	Discontinued	Acute Ischemic Stroke	DS1040-A-U103	NCT02586233 2015-001824-43 1066010708 (TW)	Tabulated Results (CT.gov)
DS-1040	Discontinued	Acute Submassive Pulmonary Embolism	DS1040-B-U107	NCT02923115 2015-005211-32	Tabulated Results (CT.gov)
DS-1040	Discontinued	Acute Ischemic Stroke	DS1040-A-J110	NCT03198715 jRCT2080223556	Tabulated Results (CT.gov) Summary Results (jRCT)
DS-1040	Discontinued	Healthy Participants	DS1040-A-E108	NCT02647307 2015-003470-32
DS-1040	Discontinued	Healthy Participants	DS1040-A-E106	NCT02560688 2015-003018-26
DS-1040	Discontinued	Acute Ischemic Stroke	DS1040-A-E102	NCT02071004
DS-1055	Discontinued	Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Other Types of Solid Cancer	DS1055-A-J101	NCT04419532 jRCT2080225196
DS-1093	Discontinued	Healthy Participants	DS1093-A-E102	NCT02142400 2014-000552-28
DS-1093	Discontinued	Kidney Disease	DS1093-A-E103	NCT02299661 2014-002331-33
DS-1123	Discontinued	Advanced Solid Tumours	DS1123-A-J101	NCT02690337 jRCT2080223031
DS-1150	Discontinued	Type 2 Diabetes Mellitus	DS1150-A-U101	NCT02004678
DS-1211	Discontinued	Pseudoxanthoma Elasticum	DS1211-A-U201	NCT05569252 2022-000676-19	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
DS-1211	Discontinued	Pseudoxanthoma Elasticum	DS1211-A-U104	NCT05025722
DS-1471	Discontinued	Advanced or Metastatic Solid Tumors	DS1471-079	NCT06074705 jRCT2031230234
DS-1971	Discontinued	Healthy Participants	DS1971-A-E106	NCT02564861 2015-002885-22
DS-1971	Discontinued	Type 2 Diabetes Mellitus; Neuropathic Pain	DS1971-A-U202	NCT02673866
DS-1971	Discontinued	Healthy Participants	DS1971-A-E105	NCT02473627 2015-000330-30
DS-1971	Discontinued	Pain	DS1971-A-J201	jRCT2080223138
DS-1971	Discontinued	Healthy Participants	DS1971-A-E104	NCT02266940 2014-003662-24
DS-1971	Discontinued	Healthy Participants	DS1971-A-E103	NCT02261376 2014-003019-13
DS-1971	Discontinued	Healthy Participants	DS1971-A-E102	NCT02190058 2014-001800-23
DS-1971	Discontinued	Healthy Participants	DS1971-A-E101	NCT02107885 2014-000240-15
DS-2248	Discontinued	Solid Cancer	DS2248-A-U101	NCT01288430 2011-002666-21	Tabulated Results (CT.gov)
DS-2325	Discontinued	Netherton Syndrome	DS2325-119	NCT05979831 2022-502853-32-00
DS-2325	Discontinued	Netherton Syndrome	DS2325-106	NCT05583669
DS-2325	Discontinued	Netherton Syndrome	DS2325-104	NCT05388903
DS-2330	Discontinued	Chronic Hemodialysis	DS2330-A-U103	NCT03305471
DS-2741	Discontinued	Atopic Dermatitis; Healthy Participants	DS2741-A-J101	NCT04211415 jRCT2080224983
DS-3078	Discontinued	Solid Cancer; Lymphomas	DS3078-A-U101	NCT01588678 2011-005988-24
DS-5573	Discontinued	Advanced Solid Malignant Tumors	DS5573-A-J101	NCT02192567 jRCT2080222535
DS-6016	Discontinued	Healthy Participants	DS6016-A-J101	NCT04818398 jRCT2051200155	Summary Results (jRCT)
DS-6157	Discontinued	Gastrointestinal Stromal Tumor	DS6157-A-U101	NCT04276415 jRCT2080225089	Tabulated Results (CT.gov) Summary Results (jRCT)
DS-7080	Discontinued	Macular Degeneration	DS7080-A-U101	NCT02530918
DS-7250	Discontinued	Diabetes	DS7250-A-J201	jRCT2080221918
DS-7309	Discontinued	Type 2 Diabetes Mellitus	DS7309-A-U102	NCT01956305
DS-7309	Discontinued	Type 2 Diabetes Mellitus	DS7309-A-U101	NCT01862939
DS-7423	Discontinued	Solid Cancer; Colorectal Cancer; Endometrial Cancer	DS7423-A-U101	NCT01364844
DS-7423	Discontinued	Solid Cancer	DS7423-A-J102	jRCT2080221724
DS-8273	Discontinued	Advanced Colorectal Cancer	DS8273-A-U103	NCT02991196
DS-8273	Discontinued	Advanced Solid Cancer; Lymphomas	DS8273-A-U101	NCT02076451
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J204	NCT02685345 jRCT2080223082
DS-8500	Discontinued	Hepatic or Renal Impairment	DS8500-A-J107	jRCT2080223081
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J205	NCT02669732 jRCT2080223072
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J203	NCT02628392 jRCT2080223014
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-U202	NCT02647320	Tabulated Results (CT.gov)
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J201	NCT02222350 jRCT2080222546
DS-8500	Discontinued	Healthy Participants	DS8500-A-J103	jRCT2080223495
DS-8500	Discontinued	Healthy Participants	DS8500-A-J108	jRCT2080223178
DS-8500	Discontinued	Healthy Participants	DS8500-A-J110	jRCT2080223244
DS-8500	Discontinued	Healthy Participants	DS8500-A-U105	NCT03699774
DS-8500	Discontinued	Healthy Participants	DS8500-A-U112	NCT02790684
DS-8500	Discontinued	Healthy Participants	DS8500-A-U109	NCT02790671
DS-8500	Discontinued	Healthy Participants	DS8500-A-J106	jRCT2080222826
DS-8500	Discontinued	Healthy Participants	DS8500-A-J104	jRCT2080222622
DS-8895	Discontinued	Advanced Solid Cancer	DS8895-A-J101	NCT02004717 jRCT2080222257
DS-9231 (TS23)	Discontinued	Acute Pulmonary Embolism	DS9231-A-U201	2017-000552-25

E

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	LIX-OS-22-01	NCT05804747
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	EDX/18/0414(2)	NCT05262322
Edoxaban	SAVAYSA® LIXIANA®	Non-valvular Atrial Fibrillation	DSCN-ETNA AF-RWS-001	NCT04747496
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	ETAF-TR-01	NCT04594915
Edoxaban	SAVAYSA® LIXIANA®	Non-valvular Atrial Fibrillation	DS-EDO-01-20-DE	NCT04519944
Edoxaban	SAVAYSA® LIXIANA®	Cardiac Disease	DU176b-C-U313	NCT03395639 2017-000475-90	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-C-A4012	NCT03247582
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-C-A4011	NCT03247569
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-D-A4010	NCT02952599
Edoxaban	SAVAYSA® LIXIANA®	Non-Valvular Atrial Fibrillation	DU176b-C-A4008	NCT02951039
Edoxaban	SAVAYSA® LIXIANA®	Non-Valvular Atrial Fibrillation	DU176B-C-U4001	NCT02943785 2016-003930-26	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation; Venous Thromboembolism	DSE-EDO-02-15-EU	NCT02950168
Edoxaban	SAVAYSA® LIXIANA®	Non-Valvular Atrial Fibrillation	DU176b-C-E314	NCT02964949 2016-001795-30	Tabulated Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DSE-EDO-05-14-EU	NCT02943993	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Non Valvular Atrial Fibrillation	DSE-EDO-04-14-EU	NCT02944019
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DSE-EDO-01-16-EU	NCT02942576 2016-003069-25 1066014172 (TW)	Tabulated Results (CT.gov) (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Non-Valvular Atrial Fibrillation	DSE-EDO-01-15-EU	NCT02866175 2016-002683-14 1056070430 (TW)	Tabulated Results (CT.gov) (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Non-valvular Atrial Fibrillation	DU176b-C-J316	NCT02801669 jRCT2080223211	Tabulated Results (CT.gov) Summary Results (jRCT)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-D-U312	NCT02798471 2016-000991-49 1066058021 (TW)	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Edoxaban	SAVAYSA® LIXIANA®	Deep Vein Thrombosis; Venous Thromboembolism	DU176b-A-U157	NCT02303431 2015-005732-18	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thrombosis; Atrial Fibrillation	DU176b-A-A144	CTR20130113 (CN)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Cancer	DU176b-D-U311	NCT02073682 2014-004708-30	Tabulated Results (CT.gov) (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-F-E308	NCT02072434 2013-003148-21	Tabulated Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Peripheral Arterial Disease	DU176b-E-U210	NCT01802775 2012-003009-88	Tabulated Results (CT.gov) (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Non-valvular Atrial Fibrillation	DU176b-C-J307	jRCT2080221674	Summary Results (jRCT)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-B-J307	NCT01857622	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-B-J306	NCT01857583	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Non-Valvular Atrial Fibrillation	DU176b-D-U211	NCT01662908	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism; Thromboembolism; Thrombosis; Deep Vein Thrombosis; Arthroplasty; Hip Replacement	DU176b-B-J209	NCT01203098 jRCT2080220798 9706593 (TW)	Tabulated Results (CT.gov) Summary Results (jRCT)
Edoxaban	SAVAYSA® LIXIANA®	Deep-Vein Blood Clots; Lung Blood Clots	DU176b-D-U305	NCT00986154 2009-014290-40 jRCT2080221010 9827603 (TW)	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-B-J304	NCT01181167 jRCT2080220743	Tabulated Results (CT.gov) Summary Results (jRCT)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-B-J303	NCT01181141 jRCT2080220770	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-B-J302	NCT01181102 jRCT2080220701 9720053 (TW)	Tabulated Results (CT.gov) Summary Results (jRCT)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-C-U301	NCT00781391 2008-004522-16 jRCT2080220747 9724061(TW)	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-C-J225	NCT00829933 jRCT2080220382	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-C-J226	NCT00806624 9611571 (TW)	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA® LIXIANA®	Venous Thromboembolism	DU176b-04	NCT01203072 jRCT2080220278	Tabulated Results (CT.gov) Summary Results (jRCT)
Edoxaban	SAVAYSA® LIXIANA®	Atrial Fibrillation	DU176b-PRT018	NCT00504556 2007-001271-11	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Thrombosis; Hip Replacement	DU176b-PRT011	NCT00398216 2006-000758-29	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Arthroplasty, Hip Replacement; Thrombosis	DU176b-PRT007	NCT00107900 2004-004415-29	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Edoxaban	SAVAYSA® LIXIANA®	Healthy Participants	DU176b-A-U158	NCT02047565
Esaxerenone	MINNEBRO®	Type 2 Diabetes	CS3150-B-J309	jRCT2080223640	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Type 2 Diabetes	CS3150-B-J308	jRCT2080223639	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Type 2 Diabetes Mellitus	CS3150-B-J204	NCT02345057 jRCT2080222722
Esaxerenone	MINNEBRO®	Diabetes	CS3150-B-J202	jRCT2080221972
Esaxerenone	MINNEBRO®	Primary Aldosteronism	CS3150-A-J307	NCT02885662 jRCT2080223294	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Essential Hypertension	CS3150-A-J303	NCT02848170 jRCT2080223269	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Hypertension With Type 2 Diabetes and Albuminuria	CS3150-A-J306	NCT02807974 jRCT2080223238	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Severe Hypertension	CS3150-A-J304	NCT02808026 jRCT2080223232	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Moderate Renal Impairment; Hypertension	CS3150-A-J305	NCT02807987 jRCT2080223233	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Essential Hypertension	CS3150-A-J301	NCT02890173 jRCT2080223293	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Essential Hypertension	CS3150-A-J302	NCT02722265 jRCT2080223121	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Hypertension; Moderate Renal Impairment	CS3150-A-J206	NCT02448628 jRCT2080222831	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Hypertension	CS3150-A-J203	NCT02345044 jRCT2080222720	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Hypertension	CS3150-A-J201	jRCT2080221876	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-C-J101	jRCT1080224760	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J112	jRCT2080223397	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J111	jRCT2080223388	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J110	jRCT2080223324	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Hepatic Impairment	CS3150-A-J109	jRCT2080223284	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J108	jRCT2080223231	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J107	jRCT2080222780	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-U106	NCT04019652
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J102	jRCT2080223421	Summary Results (jRCT)
Esaxerenone	MINNEBRO®	Healthy Participants	CS3150-A-J101	jRCT2080223418	Summary Results (jRCT)
Efatutazone	Discontinued	Colorectal Cancer	CS7017-A-J111	jRCT2080221193
Efatutazone	Discontinued	Non-Smal Cell Lung Cancer	CS7017-A-A110	NCT01199068	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Non-Smal Cell Lung Cancer	CS7017-A-A108	NCT01199055	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Solid Cancer	CS7017-A-J107	jRCT2080220936
Efatutazone	Discontinued	Lung Cancer	CS7017-A-U204	NCT01101334 2009-016083-36	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Efatutazone	Discontinued	Colorectal Cancer	CS7017-A-E201	NCT00986440 2008-005848-16	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Efatutazone	Discontinued	Colorectal Cancer	CS7017-A-U203	NCT00967616	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Cancer	CS7017-A-U102E	NCT00881569	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Lung Cancer	CS7017-A-U202	NCT00806286 2009-013428-22	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Anaplastic Thyroid Cancer	CS7017-A-U103	NCT00603941	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Neoplasm	CS7017-A-U102	NCT00408434	Tabulated Results (CT.gov)
Exatecan	Discontinued	Sarcoma	CDR0000271889	NCT00055952
Exatecan	Discontinued	Sarcoma	CDR0000271888	NCT00055939
Exatecan	Discontinued	Pancreatic Cancer	CDR0000068880	NCT00023972
Exatecan	Discontinued	Esophageal Cancer; Gastric Cancer	CDR0000068663	NCT00017212
Exatecan	Discontinued	Biliary Cancer	CDR0000067736	NCT00005938
Exatecan	Discontinued	Cervical Cancer	CDR0000067525	NCT00004866
Exatecan	Discontinued	Brain and Central Nervous System Cancer; Lymphoma; Unspecified Childhood Solid Cancer	CDR0000067330	NCT00004212
Exatecan	Discontinued	Liver Cancer	CDR0000067329	NCT00004108
Exatecan	Discontinued	Ovarian, Fallopian Tube, or Peritoneal Cancer	CDR0000067258	NCT00004060
Exatecan	Discontinued	Hematologic Cancer	CDR0000067149	NCT00004047
Exatecan	Discontinued	Breast Cancer	CDR0000067148	NCT00004046
Exatecan	Discontinued	Prostate Cancer	CDR0000067146	NCT00004045
Exatecan	Discontinued	Pancreatic cancer	CDR0000067147	NCT00003951

G

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Ghrelin	Discontinued	Anorexia	NA3801	jRCT2080220697
Ghrelin	Discontinued	Chronic Obstructive Pulmonary Disease	ASBI 307	NCT00698828 2007-007725-46	Tabulated Results (CT.gov) Summary Results (EU-CTR)

H

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Hydromorphone	NARUVEIN®	Cancer Pain	DS7113-C-J306	jRCT2080222685	Summary Results (jRCT)
Hydromorphone	NARUVEIN®	Cancer Pain	DS7113-C-J305	jRCT2080222684	Summary Results (jRCT)
Hydromorphone	NARUSUS®	Cancer Pain	DS7113-B-J304	jRCT2080222616	Summary Results (jRCT)
Hydromorphone	NARUSUS®	Cancer Pain	DS7113-B-J303	jRCT2080222615	Summary Results (jRCT)
Hydromorphone	NARURAPID®	Cancer Pain	DS7113-A-J302	jRCT2080222239	Summary Results (jRCT)
Hydromorphone	NARURAPID®	Cancer Pain	DS7113-A-J301	jRCT2080222289	Summary Results (jRCT)
Hydromorphone	NARURAPID®	Cancer Pain	DS7113-A-J201	jRCT2080222120	Summary Results (jRCT)
Hydromorphone	NARURAPID® NARUSUS®	Healthy Participants	DS7113-A-J102	jRCT2080222121

I

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Ifinatamab Deruxtecan (DS-7300)		Esophageal Squamous Cell Carcinoma	IDeate-Esophageal01 DS7300-202	NCT06644781 jRCT2031240571 CTR20250583 (CN) 1149003433 (TW) MFDS Korea
Ifinatamab Deruxtecan (DS-7300)		Small-cell Lung Cancer	IDeate-Lung03 DS7300-189	NCT06362252 jRCT2031240089
Ifinatamab Deruxtecan (DS-7300)		Recurrent or Metastatic Solid Tumors	DS7300-203	NCT06330064 2023-509632-26-00 jRCT2031240016 1139028690 (TW)
Ifinatamab Deruxtecan (DS-7300)		Small-cell Lung Cancer	IDeate-Lung02 DS7300-188	NCT06203210 2023-509628-16-00 jRCT2031230631 CTR20242805 (CN) 1139027209 (TW) MFDS Korea
Ifinatamab Deruxtecan (DS-7300)		Small-cell Lung Cancer	IDeate-Lung01 DS7300-127	NCT05280470 2024-512368-79-00 jRCT2041220019 CTR20222027 (CN) 1119031453 (TW) MFDS Korea
Ifinatamab Deruxtecan (DS-7300)		Advanced Solid Cancer	IDeate-PanTumor01 DS7300-A-J101	NCT04145622 jRCT2080224907
Influenza Vaccine Intranasal	FluMist®	Prevention of Influenza	VN0107-A-J301	jRCT2080223345	Summary Results (jRCT)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J303	jRCT2080222503	Summary Results (jRCT)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J301	jRCT2080221874	Summary Results (jRCT)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J302	jRCT2080221923	Summary Results (jRCT)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J201	jRCT2080222144	Summary Results (jRCT)
Influenza Vaccine	Influenza HA Vaccine	Prevention of Influenza	VN0104-A-J201	jRCT2080222536	Summary Results (jRCT)
Irinotecan	TOPOTECIN®	Small Cell Lung Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Ovarian Cancer; Gastric Cancer	TOP009-062	NCT01040312 jRCT1080220914
Irinotecan	TOPOTECIN®	Colorectal Cancer	TOP009-061	NCT01039506 jRCT1080220913
Irinotecan	TOPOTECIN®	Colorectal Cancer	TOP-003	NCT00284258 jRCT1080220199
Irinotecan	TOPOTECIN®	Gastric Cancer	TOP-002	jRCT1080220081	Summary Results (jRCT)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J301	jRCT2080222443	Summary Results (jRCT)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J302	jRCT2080222562	Summary Results (jRCT)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J303	jRCT2080222939	Summary Results (jRCT)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J101	jRCT2080222050	Summary Results (jRCT)
Ioforminol	Discontinued	Coronary Angiography	GE145-A-J203	jRCT2080222467
Ioforminol	Discontinued	Coronary Angiography	GE145-A-J202	jRCT2080222468
Ioforminol	Discontinued	Coronary Angiography	GE145-A-J201	jRCT2080222341

L

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Laninamivir	INAVIR®	Influenza	CS8958-B-J311	jRCT2080223343	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-B-J310	jRCT2080223342	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza (Prophylaxis)	CS8958-A-J309	jRCT2080222628	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza (Prophylaxis)	CS8958-A-J308	jRCT2080222627	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza (Prophylaxis)	CS8958-A-J307	jRCT2080221607
Laninamivir	INAVIR®	Influenza	CS8958-A-J306	jRCT2080220909	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-J305	jRCT2080220908	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-A202	jRCT2080220797 9615473 (TW)	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-J304	jRCT2080220785	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-J303	jRCT2080220784	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-J302	jRCT2080220783	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-J301	NCT00803595 9717469 (TW)	Tabulated Results (CT.gov)
Laninamivir	INAVIR®	Influenza	CS8958-A-J203	jRCT2080220782	Summary Results (jRCT)
Laninamivir	INAVIR®	Influenza	CS8958-A-J201	jRCT2080220781	Summary Results (jRCT)
Laninamivir	INAVIR®	Healthy Participants	CS8958-B-J109	jRCT2080222944	Summary Results (jRCT)
Laninamivir	INAVIR®	Healthy Participants	CS8958-A-J108	jRCT2080221402
Levofloxacin	CRAVIT®	Infections	DR3355-B-J305	jRCT2080221818	Summary Results (jRCT)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J304	jRCT2080221853	Summary Results (jRCT)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J303	jRCT2080221815	Summary Results (jRCT)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J302	jRCT2080221802	Summary Results (jRCT)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J301	jRCT2080221777	Summary Results (jRCT)
Levofloxacin	CRAVIT®	Infections	DR3355-60	jRCT2080220476	Summary Results (jRCT)

M

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
MMR Vaccine		Prevention of Measles; Mumps; Rubella	VN0102-A-J303	jRCT2080225022	Summary Results (jRCT)
MMR Vaccine		Prevention of Measles; Mumps; Rubella	VN0102-A-J302	jRCT2080225025	Summary Results (jRCT)
MMR Vaccine		Prevention of Measles; Mumps; Rubella	VN0102-A-J301	jRCT2080225026	Summary Results (jRCT)
MMR Vaccine		Prevention of Measles; Mumps; Rubella	JVC-001-P12-01	jRCT2080222978	Summary Results (jRCT)
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathic Pain	DS5565-0002-NIS-MA	NCT06812117
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathic Pain	DS5565-A-A315	NCT04094662 CTR20191151 (CN)
Mirogabalin	TARLIGE®	Central Neuropathic Pain	DS5565-A-J314	NCT03901352 jRCT2080224584 1086007912 (TW)	Tabulated Results (CT.gov) Summary Results (jRCT)
Mirogabalin	TARLIGE®	Fibromyalgia	DS5565-A-U307	NCT02496884 2014-003972-21	Tabulated Results (CT.gov) (EU-CTR)
Mirogabalin	TARLIGE®	Fibromyalgia	DS5565-A-E309	NCT02146430 2013-005161-40	Tabulated Results (CT.gov) (EU-CTR)
Mirogabalin	TARLIGE®	Fibromyalgia	DS5565-A-E311	NCT02187159 2013-005163-10	Tabulated Results (CT.gov) (EU-CTR)
Mirogabalin	TARLIGE®	Post-herpetic Neuralgia	DS5565-A-J304	NCT02318719 jRCT2080222691 1036069768 (TW)	Tabulated Results (CT.gov) Summary Results (jRCT)
Mirogabalin	TARLIGE®	Renal Impairment; Diabetic Peripheral Neuropathic Pain; Post-herpetic Neuralgia	DS5565-A-J313	NCT02607280 jRCT2080223005	Tabulated Results (CT.gov) Summary Results (jRCT)
Mirogabalin	TARLIGE®	Pain Associated With Fibromyalgia	DS5565-A-E310	NCT02187471 2013-005162-20	Tabulated Results (CT.gov) (EU-CTR)
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathic Pain	DS5565-A-J303	NCT02318706 jRCT2080222690 1036069767 (TW)	Tabulated Results (CT.gov) Summary Results (jRCT)
Mirogabalin	TARLIGE®	Pain Associated with Fibromyalgia	DS5565-A-E312	NCT02234583 2013-005164-26	Tabulated Results (CT.gov) (EU-CTR)
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathy	DS5565-A-U201	NCT01496365	Tabulated Results (CT.gov)
Mirogabalin	TARLIGE®	Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathic Pain	DS5565-A-J202	NCT01504412 jRCT2080221671 1005056988 (TW)	Tabulated Results (CT.gov) Summary Results (jRCT)
Mirogabalin	TARLIGE®	Renal Dysfunction	DS5565-A-J115	jRCT2080222129	Summary Results (jRCT)
Mirogabalin	TARLIGE®	Healthy Participants	DS5565-A-J316	jRCT1080225061
Mirogabalin	TARLIGE®	Healthy Participants	DS5565-A-A118	jRCT1080223624 CTR20170352 (CN)	Summary Results (jRCT)
Memantine	MEMARY®	Alzheimer's Disease	SUNY7017-A-J301	jRCT2080223154
Memantine	MEMARY®	Alzheimer's Disease	IE3701	jRCT1080221701	Summary Results (jRCT)
Memantine	MEMARY®	Alzheimer's Disease	MA3301	jRCT2080220079	Summary Results (jRCT)
Memantine	MEMARY®	Alzheimer's Disease	IE3501	jRCT2080220078	Summary Results (jRCT)
Morphine Sulfate	MORPHABOND®	Baseline Epidemiologic Assessment	MORPH-A-U403	NCT04033094
Milademetan	Out-licensed	Acute Myeloid Leukemia	DS3032-A-J104	NCT03671564 jRCT2080223995	Tabulated Results (CT.gov) Summary Results (jRCT)
Milademetan	Out-licensed	Acute Myeloid Leukemia	DS3032-A-U105	NCT03552029	Tabulated Results (CT.gov)
Milademetan	Out-licensed	Hematological Malignancies	DS3032-A-U102	NCT02319369	Tabulated Results (CT.gov)
Milademetan	Out-licensed	Solid Cancer; Lymphomas	DS3032-A-J103	jRCT2080222642	Summary Results (jRCT)
Milademetan	Out-licensed	Advanced Solid Cancer; Lymphomas	DS3032-A-U101	NCT01877382	Tabulated Results (CT.gov)
Milademetan	Out-licensed	Healthy Participants	DS3032-A-U115	NCT03647202
Milademetan	Out-licensed	Healthy Participants	DS3032-A-U107	NCT03614455

N

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Nafamostat	Discontinued	Healthy Participants	DS2319-A-J101	jRCT2051200153	Summary Results (jRCT)
Nimotuzumab	Discontinued	Lung Cancer	DE766-A-J303	jRCT2080222038
Nimotuzumab	Discontinued	Gastric Cancer; Gastroesophageal Junction Cancer	DE766-A-J302	1056041513 (TW)
Nimotuzumab	Discontinued	Esophageal Cancer	DE766-A-J102	jRCT2080221282
Nimotuzumab	Discontinued	Non-small Cell Lung Cancer	DE766-A-J202	jRCT2080220796
Nimotuzumab	Discontinued	Gastric Cancer	DE766-A-J201	jRCT2080220818

O

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Observational Study	No drug	Triple Negative Breast Cancer	DS1062-0007-NIS-EPI	NCT07092254
Observational Study	No drug	Advanced/ Metastatic HER2-negative Breast Cancer	U31402-0012-NIS-MA	NCT06975371
Observational Study	No drug	HER2-positive Breast Cancer	U31402-0010-NIS-MA	NCT06833268
Observational Study	No drug	Seasonal influenza	DS5269-034	jRCT1030240609
Observational Study	No drug	HER2-positive Gastric Cancer; Gastroesophageal Junction Cancer	DS8201-0014-NIS-MA	NCT06585501
Observational Study	No drug	Advanced/ Metastatic HER2-negative Breast Cancer; Advanced/ Metastatic NSCLC	DS1062-0008-NIS-EPI	NCT06686602
Observational Study	No drug	Metastatic Non- small Cell Lung Cancer (mNSCLC)	DS1062-0003-NIS-EPI	NCT06557967
Observational Study	No drug	Non-small Cell Lung Cancer (NSCLC)	DS1062-0001-NIS-MA	NCT06617390
Observational Study	No drug	Diabetic Peripheral Neuropathic Pain (DPNP); Chemotherapy-induced Peripheral Neuropathy (CIPN)	DS5565-0001-NIS-MA	NCT06546202
Observational Study	No drug	Hormone-receptor-positive Breast Cancer; HER2-low Breast Cancer; HER2-negative Breast Cancer	U31402-0005-NIS-EPI	NCT06040593
Observational Study	No drug	Non-small Cell Lung Cancer	U31402-0003-NIS-MA	NCT05769764
Observational Study	No drug	HER2-positive Breast Cancer	DSCN-EHT-NIS-BC001	NCT05769751
Observational Study	N/A	Gastric Cancer	DS-ASCAHQ-ENH-GC001	NCT05606094
Observational Study	N/A	Primary Hyper-cholesterolemiia; Mixed Dyslipidemia	DSE-BMP-01-24-EU	NCT06686615
Observational Study	N/A	Primary Hypercholestero lemia; Mixed Dyslipidemia	DSE-BMP-01-22-EU	NCT05798390
Observational Study	N/A	Hyper- cholesterolemia; Mixed Dyslipidemia	DSE-BMP-01-20	NCT04579367
Observational Study	N/A	Hyper- cholesterolemia; Mixed Dyslipidemia	SYROS-DSE-BMP-01-21-EU	NCT05546398
Observational Study	N/A	Dyslipidemic; Atherosclerotic Cardiovascular Disease; Hyper-cholesterolemia	DSE-HCL-01-19-EU	NCT04271280	Tabulated Results (CT.gov)
Observational Study	N/A	Tenosynovial Giant Cell Tumors	DS-ONC-01-15-EU	NCT02948088	Tabulated Results (CT.gov)
Observational Study	N/A	Gastric Cancer; Gastroesophageal Junction Cancer; Colorectal Cancer	DS-Screen	jRCT1080223325
Observational Study	N/A	Nonhemorrhagic Ischemic Stroke	ASBI 801	NCT01496885	Tabulated Results (CT.gov)
Observational Study	N/A	Healthy Participants (Measure of Tidal Breathing)	N/A	jRCT1080223039
Observational Study	N/A	Venous Thromboembolism	DSE-VTE-01-12	DRKS00004795
Ofloxacin	TARIVID®	Infections	8280A-PRT021	NCT00781521
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	CS0866-A-U301	NCT00151775 2015-003329-32	Tabulated Results (CT.gov) (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Metabolic Syndrome; Hypertension	DSE-866/47	NCT00676845 2007-003131-23	Summary Results (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension; Carotid Plaque	DSE-OLM-01-09	NCT01132768 2009-013342-92
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	866-447	NCT00185120
Olmesartan Medoxomil	BENICAR® OLMETEC®	Metabolic Syndrome; Hypertension	DSE-866/46	NCT00891267 2007-003130-41	Summary Results (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Diabetic Nephropathy; Type 2 Diabetes Mellitus; Proteinuria	149-011/150-008 ORIENT	NCT00141453 jRCT2080220027	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	CS0866-A-U452	NCT00949884	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Mild to moderate hypertension	SP-OLM-03-05	NCT00311155 2005-004659-36	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension; Renal Impairment	SE-866/43	NCT00151827
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension	SS-866/01	NCT00856271
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension	SS-866 CMB/01	NCT00872586
Olmesartan Medoxomil	BENICAR® OLMETEC®	Chronic Glomerulonephritis or Diabetic Nephropathy	CS0866-C-J201	NCT00914524
Olmesartan Medoxomil	BENICAR® OLMETEC®	Chronic Heart Failure; High Blood B-type (or Brain) Natriuretic Peptide Level	DSE-866-45	NCT00679484 2007-003060-22	Summary Results (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	CS0866-A-U102	NCT00151814 2015-003328-30	Tabulated Results (CT.gov) (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	866-451	NCT00430638	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Type 2 Diabetes Mellitus; Cardiovascular Disease; Kidney Disease	SE-866/44	NCT00185159 2004-000506-52	Summary Results (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	OLM004-071	NCT00858702	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	866-450	NCT00412932	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	TSP-866/01	NCT00857285	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension	SPB-OM-0106	NCT00890591	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	866-432	NCT00772499
Olmesartan Medoxomil	BENICAR® OLMETEC®	Isolated Systolic Hypertension	SE-866/37	NCT00751829
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension	SE-866/36	NCT00751751
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension	SP-OLM-01-00	NCT00185172 2005-004659-36
Olmesartan Medoxomil	BENICAR® OLMETEC®	Atherosclerosis; Essential Hypertension	SE-866/27	NCT00185185
Olmesartan Medoxomil	BENICAR® OLMETEC®	Type 2 Diabetes Mellitus; Renal Disease	SE-866/29	NCT00362960
Olmesartan Medoxomil	BENICAR® OLMETEC®	Atherosclerosis	866-422 AIMS	NCT00382213
Olmesartan Medoxomil	BENICAR® OLMETEC®	Essential Hypertension	866-440	NCT00185094
Olmesartan Medoxomil	BENICAR® OLMETEC®	Healthy Participants	866-448	NCT00185055
Olmesartan Medoxomil	BENICAR® OLMETEC®	Healthy Participants	CS0866-A-U101	2015-003005-41	Tabulated Results (EU-CTR)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	OMEGA study	jRCT1080220002	Summary Results (jRCT)
Olmesartan Medoxomil	BENICAR® OLMETEC®	Hypertension	PMS-OLM-200801	jRCT1080221127	Summary Results (jRCT)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Hypertension	DSE-SEV-02-09	NCT01101009
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Hypertension	CS8663-404	NCT00791258	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Type 2 Diabetes Mellitus; Hypertension	CS-8663-403	NCT00654745	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Hypertension	8663-402	NCT00527514	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Hypertension	CS8663-A-U301	NCT00185133
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Essential Hypertension	CS8663-A-E303	NCT00220233 2005-000450-75	Summary Results (EU-CTR)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Essential Hypertension	CS8663-A-E302	NCT00220220 2005-000447-28	Summary Results (EU-CTR)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Essential Hypertension	DSE-SEV-02-09	2009-012966-30	Summary Results (EU-CTR)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Essential Hypertension	SS8663-04	CTR20140715 (CN)
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Healthy Participants	SS8663-03	jRCT2080221540
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Hypertension	SS8663-02	jRCT2080221541
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Hypertension	SS8663-01	jRCT2080221543
Olmesartan Medoxomil + Amlodipine	AZOR® SEVIKAR®	Essential Hypertension	DAHAMLA200807 16	9716500 (TW)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR® SEVIKAR HCT®	Essential Hypertension	CS8635-A-E302	NCT00923091 2008-003534-25	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR® SEVIKAR HCT®	Essential Hypertension	CS8635-A-E303	NCT00902538 2008-003535-20	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR® SEVIKAR HCT®	Hypertension	CS8635-A-U301	NCT00649389	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR® SEVIKAR HCT®	Essential Hypertension	CS8635-SIT-11-01	NCT01838850
Olmesartan Medoxomil + Azelnidipine	REZALTAS®	Hypertension	CS0866AZ-A-J301	jRCT2080220281	Summary Results (jRCT)
Olmesartan Medoxomil + Azelnidipine	REZALTAS®	Hypertension	CS0866AZ-A-J302	jRCT2080220290	Summary Results (jRCT)
Olmesartan Medoxomil + Azelnidipine	REZALTAS®	Hypertension	CS0866AZ-A-J303	jRCT2080220439	Summary Results (jRCT)
Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR HCT® OLMETEC PLUS®	Type 2 Diabetes Mellitus	866-449	NCT00403481	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR HCT® OLMETEC PLUS®	Hypertension	CS866CM-B-E301	NCT00430508 2006-003876-37	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR HCT® OLMETEC PLUS®	Essential Hypertension	CS866CM-B-E302	NCT00430950 2006-003877-28	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Olmesartan Medoxomil; Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR® OLMETEC® BENICAR HCT® OLMETEC PLUS®	Essential Hypertension	866-443	NCT00185068
Oxycodone	OXYCODONE	Healthy Participants	DS5058-C-J106	jRCT1080223737	Summary Results (jRCT)
Oxycodone	OXYCODONE	Healthy Participants	DS5058-C-J104	jRCT1080223551	Summary Results (jRCT)
Oxycodone	OXYCODONE	Healthy Participants	DS5058-A-J101	jRCT1080223420	Summary Results (jRCT)

P

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Patritumab Deruxtecan (U3-1402)		Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric Cancer	HERTHENA-PanTumor01 U31402-277	NCT06172478 2023-507641-29-00 jRCT2031230575 1129077151 (TW) MFDS Korea
Patritumab Deruxtecan (U3-1402)		Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer	U31402-0001-EAP-MA	NCT06099639
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	HERTHENA-Lung02 U31402-A-U301	NCT05338970 2023-507964-38-00 jRCT2021220002 CTR20222222 (CN) 1119022289 (TW) MFDS Korea
Patritumab Deruxtecan (U3-1402)		Colorectal Cancer	U31402-A-U202	NCT04479436 2019-004418-32 jRCT2031200139	Tabulated Results (CT.gov) (EU-CTR) Summary Results (jRCT) Plain Language Summary (EN)
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	HERTHENA-Lung01 U31402-A-U201	NCT04619004 2024-512238-13-00 jRCT2031200186 CTR20212974 (CN) 1096027315 (TW) MFDS Korea	Tabulated Results (CT.gov) (EU-CTR)
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	U31402-A-U103	NCT04676477 jRCT2031200247 1129038729 (TW) MFDS Korea
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	U31402-A-U102	NCT03260491 2024-511205-33-00 jRCT2080224788 1086024919 (TW) MFDS Korea
Patritumab Deruxtecan (U3-1402)		Breast Cancer	U31402-A-J101	NCT02980341 jRCT2080223346	Tabulated Results (CT.gov) Summary Results (jRCT) Plain Language Summary (EN)
Pexidartinib	TURALIO®	Tenosynovial Giant Cell Tumor	PL3397-A-U4003	NCT04526704 1096017237 (TW)	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®	Tenosynovial Giant Cell Tumor	PL3397-A-J304	NCT04703322 jRCT2041200074	Tabulated Results (CT.gov)
Pexidartinib	TURALIO®️	Tenosynovial Giant Cell Tumor	PL3397-A-U401	NCT04635111
Pexidartinib	TURALIO®️	Tenosynovial Giant Cell Tumor	PL3397-A-A303	NCT04488822 CTR20201220 (CN) 1096008197 (TW)	Tabulated Results (CT.gov)
Pexidartinib	TURALIO®️	Moderate Hepatic Impairment	PL3397-A-U129	NCT04223635	Tabulated Results (CT.gov)
Pexidartinib	TURALIO®️	Tenosynovial Giant Cell Tumor; KIT-mutant Tumor; Other Solid Cancer	PL3397-A-U126	NCT03291288 1066041865 (TW)	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Advanced Solid Cancer	PL3397-A-A103	NCT02734433 1056009385 (TW)	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Melanoma; Non-small Cell Lung Cancer; Head and Neck Cancer; Gastrointestinal Stromal Tumor (GIST); Ovarian Cancer	PLX108-14	NCT02452424	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Melanoma	PLX108-13	NCT02975700	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Pigmented Villonodular Synovitis; Giant Cell Tumor of the Tendon Sheath	PLX108-10	NCT02371369 2014-000148-14	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Melanoma	PLX108-09	NCT01826448	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Glioblastoma	PLX108-08	NCT01790503	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Solid Cancer	PLX108-07	NCT01525602	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Prostate Cancer	PLX108-06	NCT01499043	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Acute Myeloid Leukemia	PLX108-05	NCT01349049	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Glioblastoma	PLX108-04	NCT01349036	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Hodgkin Lymphoma	PLX108-03	NCT01217229	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Solid Cancer	PLX108-01	NCT01004861	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO®️	Healthy Participants	PL3397-A-U128	NCT03901313	Tabulated Results (CT.gov)
Pexidartinib	TURALIO®️	Healthy Participants	PL3397-A-U122	NCT03138759	Plain Language Summary (EN)
Prasugrel	EFFIENT®	Acute Coronary Syndrome	CS747S-B-A4003	NCT03672097	Tabulated Results (CT.gov)
Prasugrel	EFFIENT®	Thrombotic Stroke	CS0747S-A-J305	jRCT2080224080	Summary Results (jRCT)
Prasugrel	EFFIENT®	Cerebrovascular Accident	CS0747S-A-J304	jRCT2080221856	Summary Results (jRCT)
Prasugrel	EFFIENT®	Cerebrovascular Accident	CS0747S-A-J303	jRCT2080221542	Summary Results (jRCT)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS0747S-B-J302	jRCT2080221511
Prasugrel	EFFIENT®	Acute Coronary Syndrome	CS0747S-B-J301	jRCT2080221302
Prasugrel	EFFIENT®	Stroke	CS0747S-A-J203	jRCT2080221011	Summary Results (jRCT)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS747S-B-U4003	NCT01587651 2011-004064-29	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS747S-B-U4002	NCT01260584	Tabulated Results (CT.gov)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS747S-B-U4001	NCT01014624	Tabulated Results (CT.gov)
Perflubutane	SONAZOID®	Prostate Cancer	DD723-B-J301	jRCT2080221271	Summary Results (jRCT)
Perflubutane	SONAZOID®	Breast Cancer	DD723-B-J302	jRCT2080221250
Perflubutane	SONAZOID®	Prostate Cancer	DD723-B-J201	jRCT2080220862	Summary Results (jRCT)
Perflubutane	SONAZOID®	Breast Cancer	DD723-B-J202	jRCT2080220863
Pravastatin	MEVALOTIN® PRAREDUCT®	Dyslipidemia	MVT-OS-21-01	NCT05120895
Pravastatin	MEVALOTIN® PRAREDUCT®	Dyslipidemia Associated With Type 2 Diabetes Mellitus	MVT-OS-15-01	NCT05107063
Pravastatin	MEVALOTIN® PRAREDUCT®	Hyperlipidemia	APPROACH-J	jRCT1080220524
Pravastatin	MEVALOTIN® PRAREDUCT®	Hyperlipidemia; Familial Hyper-cholesterolemia	CS514E-005	CTR20240177 (CN)
Pactimibe	Discontinued	Atherosclerosis; Heterozygous Familial Hyper-cholesterolemia	505-205	NCT00151788
Pactimibe	Discontinued	Coronary Artery Disease	505-202	NCT00185042
Pactimibe	Discontinued	Atherosclerosis	SE-505/14	NCT00185146
Patritumab	Discontinued	Head and Neck Cancer	U31287-A-U203	NCT02633800 2015-002222-40	Tabulated Results (EU-CTR)
Patritumab	Discontinued	Lung Cancer	U31287-A-J107	jRCT2080222789
Patritumab	Discontinued	Head and Neck Cancer	U31287-A-U106	NCT02350712 2014-002445-22
Patritumab	Discontinued	Lung Cancer; Non-small Cell Lung Cancer	U31287-A-U301	NCT02134015 2013-004371-12	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Patritumab	Discontinued	Solid Cancer	U31287-A-U105	NCT01957280
Patritumab	Discontinued	Metastatic Breast Cancer	U3-1287-A-U202	NCT01512199
Patritumab	Discontinued	Lung Cancer	U31287-A-U201	NCT01211483 2010-021082-74	Tabulated Results (CT.gov) (EU-CTR)
Patritumab	Discontinued	Non-small Cell Lung Cancer	U31287-A-U201E	2013-000104-42	Tabulated Results (EU-CTR)
Patritumab	Discontinued	Breast Cancer	U31287-A-J103	jRCT2080221730
Patritumab	Discontinued	Lung Cancer	U31287-A-J102	jRCT2080221467
Patritumab	Discontinued	Solid Cancer	U31287-A-J101	jRCT2080221225
Piclozotan	Discontinued	Parkinson's Disease	ASBI-501	NCT00623363	Tabulated Results (CT.gov)
Piclozotan	Discontinued	Acute Ischemic Stroke	SPI-103	NCT00272909 2004-002437-39	Summary Results (EU-CTR)

Q

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia; Leukemia	AC220-167	NCT06824168 CTR20252304 (CN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	QuANTUM-Wild AC220-168	NCT06578247 jRCT2061240069 CTR20244780 (CN) 1139071649 (TW)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-U202	NCT03793478 2023-510009-16-00
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-A103	NCT03723681 CTR20180051 (CN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia; Leukemia	AC220-A-U302	NCT02668653 2015-004856-24 jRCT2080223611 CTR20170661 (CN) 1056026855 (TW)	Tabulated Results (CT.gov) (EU-CTR) Summary Results (jRCT) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-J201	NCT02984995 jRCT2080223386	Tabulated Results (CT.gov) Summary Results (jRCT) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-J102	NCT02834390 jRCT2080223254	Tabulated Results (CT.gov) Summary Results (jRCT) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Relapsed or Refactory Acute Myeloid Leukemia	AC220-A-J101	NCT02675478 jRCT2080223088	Summary Results (jRCT) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-007	NCT02039726 2013-004890-28 1046058610 (TW)	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	2689-CL-2004	NCT01565668 2011-005408-13	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	2689-CL-0011	NCT01468467	Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	2689-CL-0005	NCT01390337	Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Solid Cancer	AC220-004	NCT01049893	Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-002	NCT00989261 2009-013093-41	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	CP0001	NCT00462761	Tabulated Results (CT.gov) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Hepatic Impairment	AC220-163	NCT06740799
Quizartinib	VANFLYTA®	Moderate Hepatic Impairment	AC220-A-U105	NCT04473664	Tabulated Results (CT.gov)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-165	NCT06772246
Quizartinib	VANFLYTA®	Healthy Participants	AC220-164	NCT06740825
Quizartinib	VANFLYTA®	Healthy Participants	AC220-A-U107	NCT04796831	Tabulated Results (CT.gov) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-A-U106	NCT04459598	Tabulated Results (CT.gov)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-A-U104	NCT04459585	Tabulated Results (CT.gov)
Quizartinib	VANFLYTA®	Liver Disease; Healthy Participants	AC220-016		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-015		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-014		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-012		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-008		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Participants	AC220-006		Plain Language Summary (EN)

R

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Raludotatug Deruxtecan (DS-6000)		Advanced Solid Tumor; Metastatic Solid Tumors	REJOICE-PanTumor01 DS6000-126	NCT06660654 jRCT2031240486 CTR20250888 (CN) MFDS Korea
Raludotatug Deruxtecan (DS-6000)		Solid Cancer	REJOICE-Ovarian01 DS6000-109	NCT06161025 2023-507914-28-00 jRCT2031230556 CTR20240778 (CN) 1129076405 (TW) MFDS Korea
Raludotatug Deruxtecan (DS-6000)		Renal Cancer; Ovarian Cancer	DS6000-A-U101	NCT04707248 jRCT2031220075
Rifampicin	RIFADIN®	Healthy Participants	RIFADI-A-J101	jRCT1080223619
Renadirsen	Discontinued	Duchenne Muscular Dystrophy	DS5141-A-J201	NCT04433234 jRCT2080225225
Renadirsen	Discontinued	Duchenne Muscular Dystrophy	DS5141-A-J101	NCT02667483 jRCT2080223018	Tabulated Results (CT.gov) Summary Results (jRCT)
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS011-A-U302	NCT00571519	Tabulated Results (CT.gov)
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS0011-203	NCT00143520
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS0011-A-U301	NCT00484198 2006-005047-28	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS011-A-J204	NCT00575471 jRCT2080220415
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS011-A-J205	NCT00575874
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS0011-A-U302	2007-005263-97	Summary Results (EU-CTR)
RS Virus Vaccine (VN-0200)	Discontinued	Prevention of Respiratory Syncytial Virus Infection	VN0200-091	NCT05547087 jRCT2071220051	Summary Results (jRCT)
RS Virus Vaccine (VN-0200)	Discontinued	Prevention of Respiratory Syncytial Virus Infection	VN0200-A-J101	NCT04914520 jRCT2031210069	Summary Results (jRCT)

S

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Sitafloxacin	GRACEVIT®	COPD Exacerbation Acute	DSCN-GRV AECOPD-CSIS-001	NCT05400369
Sitafloxacin	GRACEVIT®	Infections	DU6859-A-A101	CTR20130121 (CN)
Sitafloxacin	GRACEVIT®	Infections	DU6859-A-A303	CTR20130047 (CN)
Sitafloxacin	GRACEVIT®	Infections	DU6859-A-A302	CTR20130046 (CN)
Sitafloxacin	GRACEVIT®	Infections	DU6859-A-J301	jRCT2080220704	Summary Results (jRCT)
Sitafloxacin	GRACEVIT®	Infections	DU6859a-49	jRCT2080220062
Sitafloxacin	GRACEVIT®	Infections	DU6859a-48	jRCT2080220064
Sitafloxacin	GRACEVIT®	Infections	DU6859a-47	jRCT2080220065
Sitafloxacin	GRACEVIT®	Infections	DU6859a-46	jRCT2080220069
Sitafloxacin	GRACEVIT®	Infections	DU6859a-45	jRCT2080220066
Sitafloxacin	GRACEVIT®	Infections	DU6859a-44	jRCT2080220067
Sitafloxacin	GRACEVIT®	Infections	DU6859a-43	jRCT2080220063
Sitafloxacin	GRACEVIT®	Infections	DU6859a-42	jRCT2080220068
Soblidotin	Discontinued	Soft Tissue Sarcoma	CDR0000310138	NCT00064220
Soblidotin	Discontinued	Non-small Cell Lung Cancer	CDR0000301749	NCT00061854
SUN13834	Discontinued	Atopic Dermatitis	ASBI 404	NCT00717769
SUN13837	Discontinued	Acute Spinal Cord Injury	ASBI 603	NCT01502631 2012-004373-80	Tabulated Results (CT.gov) (EU-CTR)
SUN13837	Discontinued	Stroke	ASBI 802	NCT02258880
Sodium Hyaluronate	N/A	Hip Osteoarthritis	ADA 2003-01	NCT00330135

T

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Trastuzumab Deruxtecan	ENHERTU®	Endometrial Cancer	DESTINY-Endometrial02 DS8201-854	NCT07022483 jRCT2031250423 CTR20253443 (CN) 1149057881 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Recurrent or Metastatic Solid Tumors	DS8201-801	NCT07015697 jRCT2031250307 1149047725 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Non-small Cell Lung Cancer	DESTINY-Lung06 DS8201-793	NCT06899126 jRCT2071250040 CTR20252204 (CN) 1149026111 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Ovarian Cancer	DESTINY-Ovarian01 DS8201-772	NCT06819007 jRCT2051240289 CTR20251716 (CN) 1149010694 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Cancer (Observational )	DS8201-0076-NIS-MA	NCT06846996
Trastuzumab Deruxtecan	ENHERTU®	Non-small Cell Lung Cancer (Observational )	DS8201-0079-NIS-MA	NCT06809764
Trastuzumab Deruxtecan	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Cancer	Destiny-Gastric05 DS8201-724	NCT06731478 jRCT2041240173 CTR20250981 (CN) 1139086234 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer (Observational )	DSCN-EHT-NIS-BC002	NCT06210776
Trastuzumab Deruxtecan	ENHERTU®	Solid Tumors	ROMast-001	NCT06174987 2023-506330-73-00 jRCT2031230379 MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer (Observational )	DS8201-0005-CIS-MA	NCT05945732
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DESTINY-Breast15 DS8201-0001-CIS-MA	NCT05950945 2023-505616-38-00
Trastuzumab Deruxtecan	ENHERTU®	Non-small Cell Lung Cancer	ENH-DS-22004	jRCT2071220096	Summary Results (jRCT)
Trastuzumab Deruxtecan	ENHERTU®	Colorectal Cancer	DESTINY-CRC02 DS8201-A-U207	NCT04744831 2020-004782-39 jRCT2051200124 1101490991 (TW) MFDS Korea	Tabulated Results (CT.gov) (EU-CTR) Summary Results (jRCT)
Trastuzumab Deruxtecan	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	DESTINY-Gastric04 DS8201-A-U306	NCT04704934 2023-507963-20-00 jRCT2031200369 CTR20211590 (CN) 1101491216 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Non-small Cell Lung Cancer	DESTINY-Lung02 DS8201-A-U206	NCT04644237 2020-003427-42 jRCT2061200038 1101490843 (TW) MFDS Korea	Tabulated Results (CT.gov) (EU-CTR) Summary Results (jRCT)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DESTINY-Breast05 DS8201-A-U305	NCT04622319 2023-507961-24-00 jRCT2061200033 CTR20210548 (CN) 1091495386 (TW) MFDS Korea
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer; Non-small Cell Lung Cancer	DS8201-A-U106	NCT04042701 2023-509866-39-00
Trastuzumab Deruxtecan	ENHERTU®	Gastric Cancer	DESTINY-Gastric02 DS8201-A-U205	NCT04014075 2019-001512-34	Tabulated Results (CT.gov) (EU-CTR) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DESTINY-Breast04 DS8201-A-U303	NCT03734029 2018-003069-33 jRCT2080224162 CTR20191730 (CN) 1086005765 (TW)	Tabulated Results (CT.gov)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DESTINY-Breast03 DS8201-A-U302	NCT03529110 2024-511204-16-00 jRCT2080223919 CTR20190378 (CN) 1076034885 (TW)	Tabulated Results (CT.gov) (EU-CTR)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DESTINY-Breast02 DS8201-A-U301	NCT03523585 2018-000221-31 jRCT2080223959	Tabulated Results (CT.gov)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer; Urothelial Cancer	DS8201-A-U105	NCT03523572 2018-000371-32	Tabulated Results (CT.gov) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Non-small Cell Lung Cancer	DESTINY-Lung01 DS8201-A-U204	NCT03505710 2017-004781-94 jRCT2080223860	Tabulated Results (CT.gov) Summary Results (jRCT) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Colorectal Cancer	DESTINY-CRC01 DS8201-A-J203	NCT03384940 2017-003466-28 jRCT2080223752	Tabulated Results (CT.gov) (EU-CTR) Summary Results (jRCT)
Trastuzumab Deruxtecan	ENHERTU®	Neoplasm Metastasis	DS8201-A-A104	NCT03383692 jRCT2080223734 1066070886 (TW)	Tabulated Results (CT.gov) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Gastric Cancer; Breast Cancer	DS8201-A-A103	NCT03368196 1066067098 (TW)	Tabulated Results (CT.gov) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DS8201-A-J102	NCT03366428 jRCT2080223735	Tabulated Results (CT.gov) Summary Results (jRCT) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	DS8201-C-J4001	jRCT2080225138	Summary Results (jRCT)
Trastuzumab Deruxtecan	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	DESTINY-Gastric01 DS8201-A-J202	NCT03329690 jRCT2080223671	Tabulated Results (CT.gov) Summary Results (jRCT)
Trastuzumab Deruxtecan	ENHERTU®	Breast Cancer	DESTINY-Breast01 DS8201-A-U201	NCT03248492 2016-004986-18 jRCT2080223637	Tabulated Results (CT.gov) (EU-CTR) Summary Results (jRCT) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	Advanced Solid Malignant Tumors	DS8201-A-J101	NCT02564900 jRCT2080222926	Tabulated Results (CT.gov) Summary Results (jRCT) Plain Language Summary (EN)
Trastuzumab Deruxtecan	ENHERTU®	HER2-positive Breast Cancer	EUROPA T-DXd DS8201-0002-EAP-MA	NCT05458401
Tetravalent Combination Vaccine	SQUAREKIDS	Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection	DD687-A-J301	jRCT2080221313	Summary Results (jRCT)
Tetravalent Combination Vaccine	SQUAREKIDS	Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection	DD687-A-J201	jRCT2080220899	Summary Results (jRCT)
Tigatuzumab	Discontinued	Liver Cancer	CS1008-A-U204	NCT01033240 jRCT2080221104 9902874 (TW)	Tabulated Results (CT.gov)
Tigatuzumab	Discontinued	Metastatic Colorectal Cancer	CS1008-A-U105	NCT01124630
Tigatuzumab	Discontinued	Ovarian Cancer	CS1008-A-U205	NCT00945191	Tabulated Results (CT.gov)
Tigatuzumab	Discontinued	Non-small Cell Lung Cancer	CS1008-A-E202	NCT00991796 2007-004574-11	Summary Results (EU-CTR)
Tigatuzumab	Discontinued	Colorectal Cancer	CS1008-A-E203	NCT00969033 2007-005675-34	Summary Results (EU-CTR)
Tigatuzumab	Discontinued	Pancreatic Cancer	CS1008-A-U201	NCT00521404	Tabulated Results (CT.gov)
Tigatuzumab	Discontinued	Solid Cancer; Lymphomas	CS1008-A-U101	NCT00320827
Tigatuzumab	Discontinued	Solid Cancer	CS1008-A-J104	jRCT2080220861
Tivantinib	Discontinued	Inoperable Hepatocellular Carcinoma	ARQ197-A-U303	NCT01755767 2012-003308-10	Tabulated Results (CT.gov) (EU-CTR)
Tivantinib	Discontinued	Non-squamous, Non-small Cell Lung Cancer	ARQ197-A-U302	NCT01244191 2010-022365-10
Tivantinib	Discontinued	Solid Cancer; Hepatic Impairment	ARQ197-A-U160	NCT02150733
Tivantinib	Discontinued	Colorectal Cancer	ARQ197-A-U252	NCT01075048 2009-016025-34	Tabulated Results (CT.gov) (EU-CTR)
Tivantinib	Discontinued	Solid Cancer	ARQ197-A-U158	NCT01517399
Tivantinib	Discontinued	Cancer	ARQ197-A-U159	NCT01699061
Tivantinib	Discontinued	Non-CNS Germ Cell Tumors	ARQ197-A-U251	NCT01055067 2009-015400-26	Tabulated Results (CT.gov) Summary Results (EU-CTR)
Tivantinib	Discontinued	Solid Cancer	ARQ197-A-U157	NCT01149720

U

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number
U3-1565	Discontinued	Advanced Solid Malignant Tumors; Advanced Ovarian Cancer	U31565-A-U101	NCT01290471
U3-1565	Discontinued	Solid Cancer	U31565-A-J102	jRCT2080221445
U3-1784	Discontinued	Advanced Solid Cancer; Hepatocellular Cancer	U31784-A-E101	NCT02690350

V

Generic Name / Project Code	Trade Name(s)	Medical Condition(s)	Study Number	Study Protocol Registration Number	Study Results & Plain Language Summary
Valemetostat (DS-3201)	EZHARMIA®	Lung Cancer; Non-small Cell Lung Cancer	DS3201-330	NCT06644768 jRCT2031240572 CTR20244304 (CN)
Valemetostat (DS-3201)	EZHARMIA®	Solid Tumors; Gastric Cancer; Gastroesophageal Junction Cancer; Non-small Cell Lung Cancer	DS3201-324	NCT06244485 jRCT2031230614 CTR20250732 (CN)
Valemetostat (DS-3201)	EZHARMIA®	Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia/ Lymphoma	DS3201-A-U202	NCT04703192 2023-507381-13-00 jRCT2071200095 1101492968 (TW) MFDS Korea	Tabulated Results (CT.gov)
Valemetostat (DS-3201)	EZHARMIA®	Hepatic Impairment	DS3201-A-U106	NCT04276662
Valemetostat (DS-3201)	EZHARMIA®	Adult T-cell Leukemia/ Lymphoma	DS3201-A-J201	NCT04102150 jRCT2080224880	Summary Results (jRCT)
Valemetostat (DS-3201)	EZHARMIA®	Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia	DS3201-A-U102	NCT03110354	Tabulated Results (CT.gov)
Valemetostat (DS-3201)	EZHARMIA®	Non-hodgkin Lymphoma	DS3201-A-J101	NCT02732275 jRCT2080223118
Valemetostat (DS-3201)	EZHARMIA®	Healthy Participants	DS3201-A-J109	jRCT2071200043	Summary Results (jRCT)
Valemetostat (DS-3201)	EZHARMIA®	Healthy Participants	DS3201-A-J107	jRCT2080225242	Summary Results (jRCT)
Valemetostat (DS-3201)	EZHARMIA®	Healthy Participants	DS3201-A-J104	jRCT2080223846	Summary Results (jRCT)
Valemetostat (DS-3201)	EZHARMIA®	Healthy Participants	DS3201-A-J103	jRCT2080223748	Summary Results (jRCT)